Home > Insider Trading > Filing (0001209191-11-004090)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1012140	Onyx Pharmaceuticals Inc	ONXX	Biological Products, (No Disgnostic Substances) (2836)	943154463

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1365619	Laura Brege	C/O Onyx Pharmaceuticals, Inc. 2100 Powell St. Emeryville CA 94608	Evp & Chief Operating Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2011-01-18	12,500	$15.44	31,427	No	4	M	Direct
Common Stock	Disposition	2011-01-18	12,500	$35.64	18,927	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2011-01-18	12,500	$0.00	12,500	$15.44

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
62,500		2016-06-12	No	4	M	Direct

Footnotes

Includes 413 shares purchased through the issuer's ESPP.
Shares sold pursuant to a 10b5-1 plan.
The shares were sold between $35.47 and $35.71. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
Twenty-Five percent of the shares subject to the option become exercisable 1 year from the date of grant and the remainder become exercisable at a rate of 1/48th per month thereafter.